Chronodisruption in lung cancer and possible therapeutic approaches

Biomedicine and Pharmacotherapy

Volumn 65, Issue 7, 2011, Pages 500-508

  Mazzoccoli, Gianluigi ^a   Tarquini, Roberto ^b   Durfort, Tiphanie ^c,d   Francois, Jean Christophe ^c,d  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INSERM   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Chronodisruption; Circadian rhythmicity; Cortisol; FT4; GH; IGF1; IL2; Lymphocyte subpopulation; Melatonin; Non small cell lung cancer; TRH; TSH

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; INTERLEUKIN 2; MELATONIN; PROTIRELIN; SOMATOMEDIN C; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CHRONODISRUPTION; CHRONOSEQUENCE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE DETERMINATION; HUMAN; IMMUNE SYSTEM; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADENOCARCINOMA; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNOPHENOTYPING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MELATONIN; MIDDLE AGED; NEUROIMMUNOMODULATION; PITUITARY-ADRENAL SYSTEM; SECRETORY RATE;

EID: 80555131039     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.06.004     Document Type: Article

References (70)

1. Haus E Chronobiology in the endocrine system. Adv Drug Deliv Rev 2007, 59:985-1014.
2. Ayuk J., Sheppard M.C. Growth hormone and its disorders. Postgrad Med J 2006, 82:24-30.
3. Blum W.F., Albertsson-Wikland K., Rosberg S., Ranke M.B. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993, 76:1610-1616.
4. Perry J.K., Emerald B.S., Mertani H.C., Lobie P.E. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006, 16:277-289.
5. Rudd M.F., Webb E.L., Matakidou A., Sellick G.S., Williams R.D., Bridle H., et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006, 16:693-701.
6. Werner H., LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996, 68:183-223.
7. Mazzoccoli G., Giuliani A., Bianco G., De Cata A., Balzanelli M., Carella A.M., et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels. Anticancer Res 1999, 19:1397-1399.
8. Kleinberg D.L., Wood T.L., Furth P.A., Lee A.V. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocrine Rev 2009, 30(1):51-74.
9. Wu X., Yu H., Amos C.I., Hong W.K., Spitz M.R. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Nat Cancer Inst 2000, 92:737-743.
10. Gennigens C., Menetrier-Caux C., Droz J.P. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006, 58:124-145.
11. Roddam A.W., Allen N.E., Appleby P., Key T.J., Ferrucci L., Carter H.B., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008, 149(7):461-471.
12. Rinaldi S., Cleveland R., Norat T., Biessy C., Rohrmann S., Linseisen J., et al. Serum levels of IGF-I. IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010, 126(7):1702-1715.
13. Rowlands M.A., Gunnell D., Harris R., Vatten L.J., Holly J.M., Martin R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009, 124(10):2416-2429.
14. Donovan E.A., Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008, 66:91-98.
15. Humbel R.E. Insulin-like growth factors I and II. Eur J Biochem 1990, 190:445-462.
16. Mazzoccoli G., De Cata A., Greco A., Carughi S., Giuliani F., Tarquini R. Circadian rhythmicity of lymphocyte subpopulations and relationship with neuro-endocrine system. J Biol Reg Hom Agents 2010, 24(3):341-350.
17. Auernhammer C.J., Strasburger C.J. Effects of growth hormone and insulin-like growth factor on the immune system. Eur J Endocrinol 1995, 133:635-645.
18. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocrine Rev 1997, 18:157-179.
19. Maestroni G.J.M., Conti A. The pineal nehurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. J Neuroimmunol 1990, 28:167-176.
20. Pierpaoli W., Yi C. The involvement of pineal gland and melatonin in immunity and aging. Thymus-mediated, immunorecostituting and antiviral activity of thyrotropin-releasing hormone. J Neuroimmunol 1990, 27:99-109.
21. Petrovsky N., Socha L., Silva D., Grossman A.B., Metz C., Bucala B. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol 2003, 81:137-143.
22. Arendt J. Melatonin and human rhythms. Chronobiol Int 2006, 23(1-2):21-37.
23. Suzuki S., Toyabe S., Moroda T. Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol 1997, 110:500-508.
24. Mazzoccoli G., Correra M., Bianco G., De Cata A., Balzanelli M., Giuliani A., et al. Age-related changes of neuro-endocrine-immune interactions in healthy humans. J Biol Reg Hom Agents 1997, 11:143-147.
25. Mazzoccoli G., Vendemiale G., La Viola M., De Cata A., Carughi S., Greco A., et al. Circadian variations of cortisol, melatonin and lymphocyte subpopulations in geriatric age. Int J Immunopathol Pharmacol 2010, 23(1):289-296.
26. Blum K.S., Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs?. Immunol Lett 2007, 108(1):45-51.
27. Dimitrov S., Benedict C., Heutling D., Westermann J., Born J., Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 2009, 113:5134-5143.
28. Dimitrov S., Lange T., Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010, 184(1):503-511.
29. Arjona A., Boyadjieva N., Sarkar D.K. Circadian rhythms of granzyme B, perforin, IFN-gamma, and NK cell cytolytic activity in the spleen: effects of chronic ethanol. J Immunol 2004, 172:2811-2817.
30. Parmiani G., Tumor-Infiltrating T Cells - friend or foe of neoplastic cells?. N Engl J Med 2005, 353:2640-2641.
31. Bindea G., Mlecnik B., Fridman W.H., Pagès F., Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-222.
32. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6(1):24-37.
33. Zang X., Allison J.P. The B7 family and cancer therapy: costimulation and coinhibition. Cancer Res 2007, 13(18 Pt 1):5271-5279.
34. Inman B.A., Frigola X., Dong H., Kwon ED Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007, 7(1):15-30. [Review].
35. Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010;10(9):4.
36. Kabelitz D., Wesch D., He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007, 67:5-8.
37. Mazzoccoli G., Grilli M., Carughi S., Puzzolante F., De Cata A., La Viola M., et al. Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol 2003, 16(2):167-174.
38. Mazzoccoli G., Vendemiale G., De Cata A., Carughi S., Tarquini R. Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer 2010, 10(1):314.
39. Nelson W., Tong Y.L., Halberg F. Methods for cosinorrhytmometry. Chronobiologia 1979, 6:305-323.
40. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
41. Chitnis M.M., Yuen J.S., Protheroe A.S., Pollak M., Macaulay V.M. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008, 14:6364-6370.
42. Mayeenuddin L.H., Yu Y., Kang Z., Helman L.J., Cao L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL. Oncogene 2010, 29:6367-6377.
43. Resnicoff M., Burgaud J.L., Rotman H.L., Abraham D., Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995, 55:3739-3741.
44. Andrews D.W., Resnicoff M., Flanders A.E., Kenyon L., Curtis M., Merli G., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001, 19:2189-2200.
45. Lafarge-Frayssinet C., Duc H.T., Frayssinet C., Sarasin A., Anthony D., Guo Y., et al. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression. Cancer Gene Ther 1997, 4:276-285.
46. Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother1996;42:64-8.
47. Trabado S., Van Binh P.N., Martin C., Lafarge-Frayssinet C., Lone Y.C., Trojan J., et al. Stimulation of anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9. Biomed Pharmacother 2007, 61:494-498.
48. Trojan J., Johnson T.R., Rudin S.D., Ilan J., Tykocinski M.L. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993, 259:94-97.
49. Trojan L., Ly A., Upegui-Gonzalez L., Jarocki P., Shevelev A., Sierzega M., et al. Antisense anti-IGF-I therapy of primary hepatic cancer. Afr J Cancer 2009, 1:21-30.
50. Schillaci R., Salatino M., Cassataro J., Proietti C.J., Giambartolomei G.H., Rivas M.A., et al. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. J Immunol 2006, 176:3426-3437.
51. Ly A., Francois J.C., Upegui-Gonzalez L.C., Swiercz B., Bedel C., Duc H.T., et al. Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. Life Sci 2000, 68:307-319.
52. Ly A., Duc H.T., Kalamarides M., Trojan L.A., Pan Y., Shevelev A., et al. Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 2001, 54:230-239.
53. Upegui-Gonzalez L.C., Francois J.C., Ly A., Trojan J. The approach of triple helix formation in control of gene expression and the treatment of tumors expressing IGF-I. Adv Exp Med Biol 2000, 465:319-332.
54. Duca M., Vekhoff P., Oussedik K., Halby L., Arimondo P.B. The triple helix: 50 years later, the outcome. Nucleic Acids Res 2008, 36:5123-5138.
55. Francois J.C., Lacoste J., Lacroix L., Mergny J.L. Design of antisense and triplex-forming oligonucleotides. Methods Enzymol 2000, 313:74-95.
56. Oussedik K., François J.-C., Halby L., Senamaud-Beaufort C., Toutirais G., Dallavalle S., et al. Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J 2010, 24:2235-2244.
57. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
58. Bohula E.A., Playford M.P., Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003, 14:669-682.
59. Trojan J., Ly A., Wei M.X., Bierwagen M., Kopinski P., Pan Y., et al. Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients. Biomed Pharmacother 2010, 64(8):576-578.
60. Takahashi M., Fujimoto S., Takai M., Ohno K., Endoh F., Masuda Y., et al. Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer. Surg Today 1992, 22:35-39.
61. Jackson P.A., Green M.A., Marks C.G., King R.J., Hubbard R., Cook M.G. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 1996, 38:85-89.
62. Kaver I., Pecht M., Trainin N., Greenstein A., Braf Z. T lymphocyte subsets and function in the peripheral blood of patients with urological cancer. Oncology 1992, 49:108-113.
63. Eckschlager T., Radvanska J., Slaby K., Prusa R., Hochova I., Radvansky J. Changes of blood count, lymphocyte subpopulations and immunoglobulin levels in nephroblastoma long term survivors. Neoplasma 2009, 56(1):9-12.
64. Hueman M.T., Stojadinovic A., Storrer C.E., Dehqanzada Z.A., Gurney J.M., Shriver C.D., et al. Analysis of naïve and memory CD4 and CD8T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 2007, 56(2):135-146.
65. Kruger T.E., Smith L.R., Harbour D.V., Blalock J.E. Thyrotropin: an endogenous regulator of the in vitro immune response. J Immunol 1989, 142:744-747.
66. Klecha A.J., Genaro A.M., Gorelik G., Barreiro Arco M.L., Silberman D.M., Schuman M., et al. Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway. J Endocrinol 2006, 189:45-55.
67. Hellevik A.I., Asvold B.O., Bjøro T., Romundstad P.R., Nilsen T.I., Vatten L.J. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009, 18(2):570-574.
68. Brivio F., Fumagalli L., Fumagalli G., Pescia S., Brivio R., Di Fede G., et al. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. In Vivo 2010, 24:239-241.
69. Lange T., Dimitrov S., Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010, 1193:48-59.
70. Jung B., Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res 2006, 66:9789-9793.